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MEMBRANE GLYCOPROTEIN p i50,95 OF HUMAN CYTOTOXIC T CELL CLONES 
IS INVOLVED IN CONJUGATE FORMATION WITH TARGET CELLS1
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The p i50,95 heterodixner, one of three members 
of the leukocyte function associated antigen (LFA) 
family, is expressed by monocytes, granulocytes, 
NK cells, and a small percentage of lymphocytes. 
We now report that the pl50,95 glycoprotein is ex­
pressed by some cytotoxic T cell clones and that it 
is involved in cell-mediated cytolysis by these 
clones. Two CTL clones, clone JS-93 (CD3+ CD4+ 
CD8~) and clone JS-102 (CD3+ CD4" CD8+) expressed 
high levels of pl50,95 and were shown to be specif­
ically directed against HLA-DR and HLA-A2, respec­
tively. Immunoprécipitations followed by two-di­
mensional gel electrophoresis demonstrated no het­
erogeneity in the pl50,95 molecule isolated from 
both clones. Furthermore, we demonstrated that 
monoclonal antibodies (moab) directed against 
pl50,95 could inhibit the cytotoxic activity of both 
clone JS-93 and clone JS-102 (50% and 47%, respec­
tively). Single cell assays revealed the inhibition to 
occur at the level of conjugate formation rather than 
at the level of the lethal hit.
Similar results were obtained with moab directed 
against LFA-1 (pl70,95). The capacity of the moab 
directed against LFA-1 and p i50,95 to inhibit CTL 
activity and conjugate formation were additive, re­
sulting in a similar percentage of inhibition as found 
with moab directed against the common /5-chain of 
these molecules. It is concluded that at least some 
CTL clones express the pl50,95 antigen at their cell 
surface, and that this molecule, like LFA-1, acts at 
the level of conjugate formation between effector 
and target cells.
Cytolytic T lymphocytes (CTL) are crucial In the defense 
against intracellular parasites, viruses, and immuno­
genic neoplasms (1-3). CTL-mediated killing is a multi- 
step process that takes place within 10 to 15 min at 37°C 
(4). The initial step is conjugate formation followed by 
the strengthening of the CTL-target cell interaction (4- 
7). The second step involves the delivery of the lethal hit,
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followed by lysis of the target cell independently of the 
presence of the CTL (4).
Two main phenotypes of CTL clones have been de­
scribed, namely CD3+ CD4+ CD8" and CD3+ CD4~ CD8+ 
subsets (8-10). CD3+ CD4+ CD8“ CTL clones were pri­
marily found to be directed against class II major histo­
compatibility complex (MHC) antigens, whereas CD3* 
CD 4" CDS* CTL clones are mainly reactive with class I 
MHC antigens (9-12). Monoclonal antibodies (moab)3 di­
rected against CD4 and CD8 are able to prevent conjugate 
formation (13-15). However, there is recent evidence that 
the CD8 antigen may be involved in the triggering of the 
lethal hit and has a regulatory role (16, 17). Furthermore, 
several investigators noted that moab directed against 
the CD3-T cell receptor complex (18) inhibited CTL-me- 
diated lysis (13, 19-21), probably by preventing trigger­
ing of the lethal hit (13-15).
Another molecule involved in CTL-mediated lysis is the 
leukocyte function associated antigen-1 (LFA-1) (22-24). 
Monoclonal antibodies directed against this antigen have 
been shown to prevent conjugate formation (13, 25, 26), 
but are probably not involved in the delivery of the lethal 
hit (13). The role of LFA-1 is not restricted to CTL-target 
cell binding, since moab directed against this structure 
inhibit also various other cell-cell interactions, for in­
stance B-B (27, 28), B-T (29-31), T endothelial cell (32), 
and T cell-macrophage interactions (29-31).
The LFA-1 antigen consists of an a subunit of 170 
kilodaltons (kD) and a /3 subunit of 95 kD and is related 
to complement receptor 3 (CR3) (Mol, Mac-1; 165, 95 kD) 
and pi 50,95 (150, 95 kD) antigens because these mole­
cules share the 0 subunit (30, 33, 34). LFA-1 is expressed 
by all leukocytes in contrast to CR3 (35) and pl50,95  
(36-38), which have been shown to be expressed by 
monocytes, granulocytes, and NK cells (36), Monoclonal 
antibodies directed against CR3 and pl50,95 were un­
able to inhibit the mixed lymphocyte reaction and NK 
cell-mediated killing (36).
We now report that the pl50,95 antigen can be ex­
pressed on both CD3+ CD4+ CD8“ and CD3+ CD4~ CD8+ 
CTL clones. Furthermore, we provide evidence that moab 
reactive with this antigen can inhibit CTL-mediated kill­
ing at the level of conjugate formation.
MATERIALS AND METHODS
M onoclonal a n tib o d ie s .  The moab SPV-L7 (IgGl), S-HC1 3 
(IgG2b), and  Bear-1 (IgGl) a re  directed against the ^-chains of hum an
3 Abbreviations used in this paper: LFA-1, leukocyte function associ­
ated antigen 1; moab, monoclonal antibody; TEA, triethanolamine; kD, 
kilodalton; E:T, effector to target cell.
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LFA-1, p i 50,95, and CR3 (Mol, Mac-1), respectively (30, 36). The 
moab CLB-54 (IgGl) reacts w ith the common /?-chain of th is  antigen 
family and  w as kindly provided by Dr. F. Miedema (Central Labora­
tory of the  N etherlands Red Cross Blood Transfusion Service, Am­
sterdam, The Netherlands) (30, 39). SPV-L7 and CLB-54 w ere ob­
tained after fusion of SP2/0 myeloma cells with spleen cells of mice, 
immunized w ith T lymphocytes. The moab were selected for their 
capacity to inhibit CTL activity. The moab Bear-1 and  S-HC1 3 were 
obtained afte r fusion of SP2/0 myeloma cells with spleen cells of 
mice im munized with monocytes and hairy cell leukem ia cells, re ­
spectively. The following moab were used as controls: SPV-T3A 
(anti-CD3, IgG2b), CEM (anti-KLH, IgGl), anti-Leu-14 (B cell specific, 
IgG2b).
Cell Lines a n d  T  cell c lones . Two different hum an cytotoxic T  cell 
clones were m ainly used in th is study, a CD3+ CD4+ CD8" clone (JS- 
93) and  a CD3+ CD4~ CD8+ clone (JS-102). These clones were directed 
against HLA-DR and HLA-A2, respectively (40), The specificities of 
the CTL clones JS -104, -107, -122, -132, and -141, all directed 
against JY, have been described (40). The T cell clones were cultured 
in serum -free medium as described (41). The hum an Epstein-B arr 
virus (EBV) transform ed B cell line JY and the B cell line Daudi were 
cultured in RPM I1640 supplem ented with 5% fetal calf serum  (FCS).
Immunofluorescence. Cells were incubated {30 m in, 0°C) in phos­
phate-buffered saline (PBS) containing 1% bovine serum  album in 
(BSA; Sigma Chemical Co., St. Louis, MO) and 0,01% sodium  azide 
with appropriate dilutions of the different moab followed by incu­
bation w ith fluorescein isothiocyanate (FITC)-labeled goat F(ab')2 
anti-m ouse IgG antibody (Nordic, Tilburg, The Netherlands) for 30 
min a t 0°C. The relative fluorescence intensity w as m easured by 
FACS IV analysis, which w as calculated as
fluorescence intensity  of a moab reactive with the cells 
fluorescence intensity of a moab nonreactive w ith  th e  cells
lysis buffer w as removed by centrifugation at 100,000 x G for 30 
min In an  air-driven centrifuge  (Beckman instrum ents, Palo Alto, 
CA). Lysates w ere precleared fu rth e r by successive incubations w ith  
formalin-fixed S taphylococcus aureus  bacteria (strain Cowan I) and 
mouse IgG coupled to protein  A-Sepharose. Precleared lysates were 
incubated for 3 to 4 h r w ith  a nonspecific moab coupled to protein 
A-Sepharose. T he im m unopreclpitates were removed from  the ly­
sa tes by centrifugation a t  13,000 x G. Precipitates were resuspended 
in 0.2 ml TEA/NaCl buffer w ith  0.5% sodium deoxycholate and were 
centrifuged for 15 sec a t  13,000 x  G. Subsequently immunoprecip- 
itates were w ashed extensively in 0.01 M TEA/HC1, pH 7.8, 0,2% 
Nonidet P-40.
E n zy m e  trea tm en ts .  N euram inidase treatm ent was carried out 
on im m unopreclpitates for w hich  protein A 'Sepharose beads were 
resuspended in  50 jul of 0 .05 M sodium acetate, pH 5.5, 0.9% NaCl,
0.1 % CaCl2, 1 mM phenyl m ethyl sulfonyl fluoride (PMSF) and 0.1 U 
per neuram inidase sam ple (Sigma N2876), and incubation took place 
for 3 h r a t  37°C while shaking.
Electrophoresis a n d  autoradiography. SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) w as carried out on vertical slab gels 
according to a  m odification of th e  procedure of Laemmll (47). Two- 
dim ensional gel electrophoresis w as done according to the method 
of O’Farrell (48). For isoelectric focusing, ampholytes (LKB, Bromma, 
Sweden) of pi 3 ,5  to 10, 4 to 6, and  5 to 8 were used in a ratio of 
1:1:4 in  sam ple buffer an d  gel. Samples were dissolved in  8.8 M 
urea, 0.4% SDS, 5% 2-m ercaptoethanol, and 0.2% ampholytes. After 
45 min, an  equal volume of 8 .8  M urea, 2% Nonidet P-40, 5% 2- 
m ercaptoethanol* and 2% am pholytes was added and  electrophoresis 
w as perform ed (16 h r  a t 300 V followed by 4 h r  at 800 V). The 
second dim ension consisted of a  7.5% SDS-polyacrylamide gel. Ko­
dak XAR-5 film  was used  in  com bination with intensifier screens 
(Cronex L ightning Plus; D upont Chemical Co., Newton, CT) for au ­
toradiography of *25I-labeled m aterials.
51CR-release assay . Cytotoxicity assays were carried ou t in mi­
crotiter plates w ith U-shaped wells as described (8). The capacity of 
moab to block the cytotoxic activity of CTL clones w as determ ined 
by incubating 1 or 5 x 103 effector cells with or w ithout m oab for 
15 m in a t room tem perature. After this incubation period, 1 x  103 
51Cr-labeled JY  cells were added. Subsequently, the m icrotiter plates 
were centrifuged a t 50 X G and were incubated for 4 h r  a t 37°C. The 
percent specific B1Cr release was calculated as described (10, 42).
Single cell a ssa y .  The single cell assay, which w as used to deter­
mine the capacity of various moab to inhibit binding of effector cells 
to target cells was performed according to a method developed by 
Grimm, Bonavida, and Bradley (43, 44). One hundred m icroliters of 
carboxy fluorescein-labeled effector cells (2 x 10e/ml) in Iscove’s 
modified MEM (Gibco, Glasgow, Scotland), supplemented w ith  0.25% 
BSA and 200 /¿I of target cells (2 x 106/nil), were mixed in  10 x 75- 
mm glass tubes in the presence or absence of m oab an d  were 
equilibrated to 30°C in a w aterbath  for 10 min. After th is  incubation  
period the m ixture was centrifuged for 5 min at 200 x  G, and  th e  
su p ern a tan t w as carefully removed. Subsequently, 50 pi m edium  
were added, followed by 50 ¡j.1 medium containing 1% agarose, w hich 
was kept a t 39°C. (The agarose used in this assay w as a  blend of 
Sigma type I and  VII agarose in a ratio of 1:5, respectively.) A fter th e  
cell pellet had  been resuspended, the agarose-cell suspension  w as 
plated on microscopic slides th a t had been precoated w ith  agarose. 
After gelation of the  agarose, the slides were placed in Iscove’s 
medium w ith  0.25% BSA and were incubated for 3 h r  a t  37°C in a  
humidified 5% C 02 atm osphere. After this incubation step  th e  cells 
were stained  with 0.4% trypan  blue dissolved in PBS for 10 min, 
followed by fixation with 0,6% formalin. The total num ber of con­
jugates w as calculated according to the formula
^  ^  A total num ber of conjugated effector cells ,
% Conjugates « ------------- -------- -— r „  7------ 7,----------*  100%total num ber of effector cells
The percentage of kill w as enum erated according to th e  form ula
y  Kill = dead num ber of conjugated target cells ^
° total num ber of conjugates
Radtolabeting and  immunoprécipitation. Cell su rface  radioiodi- 
nation  w ith Na 125I (Amersham, UK) was catalyzed by 1,3,4,6-tet- 
rachloro-3a,6o:diphenylglycoluril (Iodogen; Pierce Chem ical Co., 
Rockford, IL) (45) as described (46). For im m unoprécipitation (46), 
radiolabeled cells were lysed with 1% Nonidet P-40 in  0.01 M trie th - 
anolamine-HCl, pH 7,8, 0.15 M NaCl, 1 mM phenylm ethylsulfonyl 
fluoride, 0 ,02  mg/ml ovomucoid trypsin inhibitor (Sigma; TEA/NaCl 
buffer). Nuclear debris w as removed from the lysates by cen trifu ­
gation a t 13,000 x G for 15 m in a t 4°C. Material insoluble in th e
RESULTS
Expression oj p  150,95 by CTL clones. The pl50,95  
antigen has been shown to be expressed on only a minor 
population of peripheral blood lymphocytes (36). Further­
more, it has been reported that immunoprécipitations 
carried out with antibodies to the common /9-chain of the 
LFA-1 family from CTL clones sometimes show the pres­
ence of the p i50.95 antigen (33, 49), This prompted us 
to screen our CTL clones for reactivity with the S-HC1 3 
moab (anti-pl50,95a). The expression varied widely be­
tween the 16 CTL clones that were tested and was also 
variable in time within the individual clones (results not 
shown). Two clones were selected for detailed analysis, 
clone JS-93 (CD3+ CD4+ CD8~) and clone JS-102 (CD3+ 
CD4*~ CD8*), which expressed high levels of the pl50,95  
antigen (relative fluorescence intensity >10) as shown by 
immunofluorescence (Fig. 1). Furthermore, these clones 
were found to be reactive with moab directed against 
LFA-1, but not with moab directed against CR3, the third 
member of the LFA-1 family (Fig. 1). Similar results were 
obtained with the other CTL clones (not shown).
Inhibition of the cytotoxic activity of the CTL clones. 
It is well established that moab directed against the 
LFA-1 a- and jS-chain are able to inhibit the lytic activity 
of CTL clones. Because the «-chains of LFA-1 and 
p i50,95 are associated with a common /?-chain, and are 
therefore structurally related, we tested whether anti­
bodies directed against p i50,95« could block CTL activ­
ity. As depicted in Table 1, moab directed against the a- 
and /3-chains of LFA-1 and p 150,95 were able to inhibit 
the cytotoxicity of both clone JS-93 and clone JS-102. In 
addition, the moab SPV-T3b (anti-CD3) blocked the cy­
totoxicity of both clones. In contrast, the moab Bear-1, 
which reacts with CR3, and the moab CEM (anti-KLH) 
were ineffective. Similarly, other moab directed against 
CR3 (OKM-1 ) were unable to inhibit cytotoxicity. At low 
effector to target cell (E:T) ratios, the inhibition was more
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Figure I. The expression of the LFA-1 family antigens on the CTL 
clones JS-93 and JS-102 as measured by immunofluorescence. The moab 
Bear-1 (CR3 a), SPV-L7 (LFA-1 a). S-HCl 3 (pl50,95a), and CLB-54 (com­
mon j9) were used ina 1/500 dilution of ascites. The moab CEM {anti­
keyhole limpet hemocyanin) and anti-Leu-14 (B cell specific) served as 
negative controls for the IgGl and IgG2b moab, respectively. Because no 
differences were observed between reaction patterns of CEM or anti-Leu- 
14, only one control Is shown.
pronounced than at high E:T ratios.
Combinations of the antibodies directed against the 
pl50,95 and LFA-1 a-chains resulted in additive blocking 
effects on the cytolytic action of both clones (Table 1). In 
addition, it is observed that the CTL activity of several 
other clones with a low expression of pl50,95 could not 
be inhibited significantly by moab directed against 
p i50,95 alone (Table II). Although anti-LFA-1 a moab 
could inhibit CTL activity, a much higher inhibition was 
observed if a combination of anti-LFA-la and anti- 
pl50,95a moab were used, indicating that anti-pl50,95 
under these conditions can synergize with anti-LFA-1. 
Furthermore, we noted that inhibition of CTL activity by 
anti-jft-chain moab was comparable to the inhibiton found 
with mixtures of anti-LFA-1 a or anti-p 150,95a moab
(Table II). These results indicate that both LFA-1 and 
p i50,95 are involved in the process of cell-mediated cy- 
to lysis.
Inhibition of conjugate formation by moab. Several 
investigators have shown that moab directed against 
LFA-1 block cell mediated cytolysis at the level of conju­
gate formation (13, 25, 26). To determine whether the 
inhibiton of CTL activity by moab directed against 
p i50,95 was also caused by the inhibiton of conjugate 
formation, single cell assays were carried out. As shown 
in Table III, both moab directed against pl50,95o: and 
the LFA-la were able to inhibit conjugate formation of 
clone JS-93 and clone JS-102 with JY cells. Mixtures of 
these moab had additive blocking effects and were as 
effective in inhibiting conjugate formation as moab di­
rected against the common /3-chain. In addition, it is 
shown that SPV-T3b (anti-CD3) did not prevent conjugate 
formation but was able to inhibit CTL-mediated killing 
(Table III). Conjugates formed in the presence of moab 
directed against the LFA-1 family antigens showed the 
same ratio viable/non viable target cells as control sam­
ples. These results indicate that the LFA-1 family anti­
gens do not play a significant role in the delivery of the 
lethal hit.
Recently it has been described that CTL clones can 
form nonspecific conjugates with target cells that do not 
express the specific antigen to which the CTL is directed 
(13, 26). Although conjugates are formed, lysis of these 
target cells does not occur (13). This process was shown 
to be LFA-1 dependent. To investigate whether p i50,95 
is also involved in this “antigen nonspecific” conjugate 
formation, clone JS-93 and clone JS-102 were conjugated 
to Daudi cells, which cannot be lysed by these clones, 
since they do not express class I or proper class II mole­
cules (40). As shown in Table IV, formation of these 
nonspecific conjugates could be inhibited both by moab 
directed against pl50,95 and against LFA-1. From these 
data it is concluded that the inhibition of cell-mediated 
cytolysis by moab directed against pl50,95 and LFA-1 is 
primarily caused by inhibition of conjugate formation 
and not by blocking of the delivery of the lethal hit.
Biochemical analysis of p i 50,95 on CTL clones. As 
mentioned above, clone JS-93 has the CD3+ CD4+ CD8~ 
phenotype, whereas clone JS-102 has the CD3+ CD4- 
CD8+ phenotype. To investigate whether the different 
CTL clones expressed biochemically identical p i50,95, 
two-dimensional gel electrophoresis was performed from 
iodinated material. The p i50,95 a- and ^-chains were
TABLE I
Inhibition of CTL activity by moaba
% Inhibition of CTL Activity
Clone JS-93 Clone JS-102 
moab Antigen ------------------------------------  ------------------------—
E:T ratio E;T ratio
5:1 1:1 5:1 1:1
Bear-1 CR3a 2 ± 3 3 ± 3 3 ± 5 1 ± 3
SPV-L7 LFA-1 a 34 ± 5 55 ± 10 30 ± 8 49 ± 8
S-HCl 3 p l50 ,95a 26 ± 6 50 ± 9 34 ± 6 47 ± 7
CLB-54 Common 0 38 ± 8 65 ± 4 49 ± 7 60 ± 10
S-HCl 3 + SPV-L7 40 ± 6 72 ± 8 54 ± 11 80 ± 11
SPV-T3b CD3 78 ± 12 98 ± 4 65 ± 8 85 ± 7
CEM KLH 1 ± 1 0 ± 2 l ±  2 0 ± 4
a CTL clones were mixed with 5ICr-labeled JY cells and incubated for 4 hr in the presence of moab (10 /tg/ml) as 
indicated. In the absence of moab the cytotoxicity always exceeded 30%. Mean percentages inhibition ± SD of four 
experiments are shown. The phenotypes of clones 93 and 102 are CD3* CD4+ CD8~ and CD3* C4" CD8+, respectively.
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TABLE II
Synergistic effects of moab on the cytotoxic activity of weakly p i  50,95-positive CTL clonesa
moab
i
Antigen
JS-104
% Inhibition of Cytotoxicity 
CTL clone 
JS-107 JS-122 JS-132 JS-141
Bear-1 CR3a 4 0 2 3 0
SPV-L7 LFA-1 a 25 25 48 27 30
S-HCI 3 pl50,95a 14 10 3 2 0
CLB-54 Common ß 52 41 62 54 38
S-HCl 3 + SPV-L7 48 37 64 44 42
SPV-T3b CD3 72 66 83 68 92
CEM KLH 0 3 1 4 2
% pl50,95-positive cells 55 78 25 33 18
a CTL clones were mixed with 51Cr-labeled JY cells (ratio 2:1) and incubated for 4 hr in the presence of moab (10 Mg/ 
ml), as indicated. In the absence of moab the cytotoxicity always exceeded 25%. The percentage of inhibition of cytotoxicity 
of representative experiments of five CTL clones are shown. The clones 104, 107, 122, and 141 expressed CD4 but not 
CD8, whereas clone 132 was shown to be CD4" CD8*. The percentage of p 150,95-positive ceils was determined by FACS 
IV analysis. The relative fluorescence intensity did not exceed 3 (see Materials and Methods).
TABLE III
Inhibition of different stages o f the cytotoxic reaction o f CTL clones against J Y  cells by moab'
% Inhibition
A .. Clone JS-93b Clone JS-102b moab Antigen _________________________ __________________
Conjugate T , Conjugate _ ,
formation S formation s
Bear-1 
SPV-L7 
S-HCl 3 
CLB-54
S-HCl 3 + SPV-L7
SPV-T3b
CEM
CR3a 
LFA-1 a 
pl50,95<* 
Common ß
CD3
KLH
0 ± 4 
38 ± 8 
27 ±  3 
65 ± 12 
55 ± 10 
2 ± 4 
2 ±  4
1 ± 3 
3 ±  4 
4 ± 4 
3 ± 3
2 ± 4 
46 ± 10
0 ±  2
0 ±  3 
42 ± 12
24 ± 6
64 ± 5
68 ± 7
0 ± 2
1 ± 3
3 ± 2
1 ± 3 
0 ± 4
4 ± 3 
4 ± 4
56 ± 11
2 ± 1
a Single cell assays were carried out as described in Materials and Methods. In the absence of moab the percentage of 
conjugate formation and target cell lysis was 50 ± 10% and 48 ± 15%, respectively, for both clones. Mean percentages of 
inhibition ± SD of four experiments are shown. The moab were added at a concentration of 10 ^g/ml. The phenotypes of 
clones 93 and 102 are CD3+ CD4+ CD8" and CD3+ CD4~ CD8+, respectively, 
bE:T ratio 1:1.
TABLE IV
Inhibition of non specific conjugate formation between CTL and
Daudi cells by moaba
moab Antigen
% Inhibition of Conjugate 
Formation
Clone JS-93b Clone JS-1026
Bear-1 CR3<* 2 ± 4 1 ± 1
SPV-L7 LFA-1 a 63 ± 7 65 ± 4
S-HCl 3 pl50,95a 30 ± 8 35 ± 7
CLB-54 Common ß 85 ± 5 75 ± 11
S-HCl 3 + SPV-L7 85 ± 9 86 ± 8
SPV-T3b CD3 3 ± 3 1 ± 1
CEM KLH 0 ± 2 1 ± 2
“ Single cell assays were carried out as described in Materials and  
Methods. Both clone 93 and clone 102 were not able to lyse Daudl cells 
as measured by the chromium-release assay (40). In the absence of moab 
the percentage of conjugate formation was 65% ± 1 5  for both clones. 
Values represent mean ± SD of four experiments. The moab were added 
at a concentration of 10 fig/ml. The phenotypes of clone 93 and 102 are 
CD3+ CD4+ CD8~ and CD3+ CD4“ CD8+, respectively. 
bE:T ratio 1:1.
found to be slightly heterogeneous in charge, but no 
significant differences were observed between the clones 
(Fig. 2A). To reduce the charge heterogeneity, sialic acids 
were removed by neuraminidase treatment. The PI of the 
pl50,95 «-chain shifted for both clones from 5.7-6.1 to 
a PI of 6.0-6.2 (Fig. 2B). Interestingly, the 0-chain of 
pl50,95 separated into four distinct spots, probably due 
to incomplete digestion or other posttranslational modi­
fications. No significant differences were observed be­
tween the clones. Taken together, these results indicate 
that the pl50,95 antigen is nonpolymorphic expressed 
by CTL clones with different phenotypes.
DISCUSSION
Evidence is provided that the p i50,95 antigen can be 
expressed by both class I and class II HLA-specific CTL 
clones. Monoclonal antibodies directed against p i50,95 
are demonstrated to inhibit the cytotoxic reaction at the 
level of conjugate formation. Furthermore, the mode of 
action of p i 50,95 is similar to that of LFA-1, and additive 
inhibitory effects were observed if mixtures of moab 
directed against both antigens were used. In addition, 
synergistic effects were observed in those situations 
where anti-p 150,95 moab had no significant blocking 
effects. Finally, the p i50,95 antigen was not found to be 
heterogeneous, since biochemical analysis of the pi 50,95 
antigen derived from different CTL clones showed iden­
tical results.
Sanchez-Madrid et al. (33) described a variable pres­
ence of the p l50,95 antigen in lysates of CTL clones, 
since they frequently observed the presence of a 150 kD 
band in immunoprécipitations from CTL clones with 
moab directed against the /3-chain of the LFA-1 family. 
These researchers suggested that the variability of 
expression might be attributed to variations in the pres­
ence of feeder cells. Immunofluorescence experiments 
with moab directed against p i50,95 revealed the expres­
sion of this antigen on CTL clones (Fig. 1). During the 
preparation of this paper, similar findings were reported 
by Miller et al. (50). The possibility that our results are 
due to the expression of the p i50,95 antigen on mono­
cytes present in the feeder cell suspensions, instead of 
on CTL clones, could be excluded for several reasons.
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Figure 2 . Two-dimensional character­
ization of the p i 50*95 antigen precipi­
tated from a CD4+ (clone JS-93) and a 
CD8+ (clone JS-102) CTL clone. The first 
dimension Involved an isoelectrofocusing 
(IEF) followed by SDS-PAGE (SDS) In the 
second dimension. A , Untreated lmmu- 
noprecipitates; neuraminidase-treated 
immunoprecipitates.
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First, some CTL clones (clone JS-93 and JS-102) ex­
pressed the p i50,95 molecule, with a high intensity on 
100% of the cells (Fig. 1) in the absence of feeder cells. 
Second, some CTL clones were extensively washed and 
subsequently cultured for 3 wk or longer in the presence 
of IL 2 but without the addition of feeder cells and still 
expressed the p i50,95 antigen (not shown). Third, the 
CTL clones 93 and 102 are shown to have a functionally 
active p i50,95 antigen.
It is well documented that LFA-1, CR3, and p i50,95 
share a common /3 subunit (30, 33-38). Monoclonal anti­
bodies directed against the LFA-1 a- or /3-chain have been 
described to inhibit CTL function (13, 22-25, 35). In 
addition to the structural resemblance between LFA-1 
and pi 50,95, our present data also show functional sim­
ilarities, since moab directed against p i50,95a were also 
able to inhibit CTL function (Table I). Monoclonal anti­
bodies directed against CR3 were ineffective due to the 
absence of this antigen on CTL clones.
Furthermore, we (Table I) and other investigators ob­
served that moab directed against the common jS-chain 
of the human LFA-1 family antigens are generally more 
potent Inhibitors of CTL function than moab to LFA-1 
alone (34, 49-52). Because the presence of p i50,95 on 
CTL clones has not been described in this respect, these 
results may be explained by the assumption that the /3- 
chain plays a major role in CTL-target cell interactions 
(52). On the basis of our results, we do not reject such a 
possibility, but advocate that the potent inhibitory effects 
of anti-common /3-chain antibodies can be attributed to
the blocking of both p i50,95 and LFA-1. This notion is 
supported by the finding that mixtures of moab directed 
against the «-chains of LFA-1 and p l50t95 are at least 
as effective in inhibiting CTL function as moab directed 
against the common /3-chain (Table I). In addition, results 
of preliminary experiments indicate that pi 50,95-nega­
tive CTL clones can be equally well blocked by anti- 
LFA-1 a moab as by anti-/3-chain moab.
The cytotoxic activity of CTL clones with a low expres­
sion of pl50,95 could not be inhibited significantly by 
moab directed against p i50,95 alone. These clones were 
blocked more effectively by anti-common /3-chain anti­
bodies than by moab directed against the «-chain of LFA- 
1. Interestingly, combinations of moab directed to 
p i50,95 and LFA-1 «-chains are as potent in inhibiting 
the function of these CTL clones as anti-/3-chain moab 
alone (Table II). The experiments suggest that under cer­
tain conditions LFA-1 a and p i50,95 can act synergisti- 
cally.
Of interest are the findings that conjugate formation 
between monocytes and target cells can also be inhibited 
by moab directed against LFA-1 and pl50,95 (53). In this 
combination, target cell lysis was not observed. These 
results are comparable to our data obtained with Daudi 
cells that were conjugated to CTL (Table IV) without being 
killed due to the absence of the antigens needed for 
specific recognition. Because alloantigen recognition is 
probably preceded by nonspecific adhesion of cytotoxic 
T cells and target cells (13, 26), we concluded that both 
LFA-1 and pl50,95 play an important role in the initial
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(aspecific) conjugation formation of effector cells and 
target cells.
Until now, the mechanism that regulates the variable 
expression of pi 50,95 on T cells is unknown and requires 
further study. Preliminary experiments demonstrated 
that IFN-7, IL 1, and IL 2 cannot modulate the expression 
of pi 50,95. The effects of different feeder mixtures are 
currently under investigation.
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